LMU Klinikum
lmu-klinikum.deTotal trials
51
Active
18
Phase 3
1
Total enrollment
42,808
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| clemastine | — | — | — | — | — | 1 |
Next readouts
- 2026-11
Top conditions
- Tricuspid Regurgitation5
- Inclusion Body Myositis4
- Heart Failure3
- Mitral Regurgitation3
- Coronary Artery Disease3
- Basal Cell Carcinoma2
- Pompe Disease2
- Myotonic Dystrophy2
Frequently asked questions about LMU Klinikum
- How many clinical trials does LMU Klinikum have on ClinicalTrials.gov?
- LMU Klinikum is listed as the lead sponsor on 51 clinical trials in ClinicalTrials.gov, 18 of which are currently active (recruiting, enrolling, or ongoing).
- How many of LMU Klinikum's trials are in Phase 3?
- 1 of LMU Klinikum's trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does LMU Klinikum focus on?
- LMU Klinikum's most-studied conditions on ClinicalTrials.gov are Tricuspid Regurgitation, Inclusion Body Myositis, Heart Failure, Mitral Regurgitation, Coronary Artery Disease.
- When are LMU Klinikum's next clinical trial readouts?
- LMU Klinikum has 1 upcoming primary-completion readout tracked here; the soonest is “Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity”, expected around 2026-11.